Clinical Trials Logo

Papillary Thyroid Cancer clinical trials

View clinical trials related to Papillary Thyroid Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06316895 Not yet recruiting - Clinical trials for Papillary Thyroid Cancer

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Start date: April 1, 2024
Phase:
Study type: Observational

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;

NCT ID: NCT06133374 Not yet recruiting - Clinical trials for Papillary Thyroid Cancer

Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples

Start date: June 2024
Phase:
Study type: Observational

The purpose of this study is to determine whether results from a fine needle biopsy are the same as results from a larger sample that is acquired from the surgical pathology using the Thyroid GuidePx® test in patients with papillary thyroid carcinoma.

NCT ID: NCT04664413 Not yet recruiting - Clinical trials for Papillary Thyroid Cancer

Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma

ABOUT
Start date: February 1, 2021
Phase:
Study type: Observational

BRAFV600E is the most frequent oncogene in Papillary thyroid carcinoma (PTC). It correlates with greater extension, lymph node metastasis, and advanced stage. However, the prognostic value of BRAFV600Eis weak and the search of this mutation is not recommended in clinical management of thyroid cancer. PTC are characterized by intratumor heterogeneity with wild-type and BRAFV600E tumoral cells. In a previous study, the BRAFV600E/BRAFwild-type ratio correlated with patient age, tumor volume, lymph node metastasis and with worst disease outcome. While the existence of intratumor heterogeneity in PTC is supported by many evidences, its extension, biological significance and clinical utility is questioned and must be further investigated. Primary endpoint of the study is to determine the relationship between the percentage of BRAFV600E alleles and outcome in PTC patients. Secondary endpoints are to determine the mean and median BRAFV600E/BRAFwild-type allele ratio in heterogeneous tumors; determine the relationship between the percentage of BRAFV600E alleles and clinicopathological features. The study protocol entails the assessment by digital-droplet PCR the BRAFV600E/BRAFwild-type allele ratio in a series of PTC and its correlation with clinicopathology features and outcome.